Endocrinology
Insulin Mechanism
Insulin signaling, GLUT4 trafficking, and how diabetes breaks glucose homeostasis
Insulin is a 51-amino-acid peptide hormone (two chains, A and B, linked by disulfides) secreted by pancreatic β cells in islets of Langerhans in response to rising blood glucose. It binds the insulin receptor (a tetrameric tyrosine kinase) on muscle, fat, and liver cells, triggering the IRS-1 / PI3K / Akt pathway. The signature effect: GLUT4 glucose transporters translocate from intracellular vesicles to the plasma membrane, allowing glucose entry into muscle and adipose. Insulin also stops hepatic gluconeogenesis, promotes glycogen synthesis, and drives lipid storage. Type 1 diabetes — autoimmune destruction of β cells, requires exogenous insulin. Type 2 diabetes — peripheral insulin resistance plus β cell exhaustion. Diabetes affects ~537 million adults globally (IDF 2021).
- Insulin structure51 aa, A chain (21) + B chain (30), 3 disulfides
- DiscoveredBanting & Best, 1921 (Toronto)
- Receptor typeReceptor tyrosine kinase (α₂β₂ tetramer)
- Key transporterGLUT4 (muscle, fat — insulin-responsive)
- Fasting glucose normal70-99 mg/dL (3.9-5.5 mmol/L)
- HbA1c diabetes threshold≥6.5% (≥48 mmol/mol)
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why insulin matters
- Glucose homeostasis. Master regulator of postprandial glucose disposal.
- Diabetes treatment. Lifesaving in type 1; adjunct in advanced type 2.
- Anabolism. Promotes protein synthesis, lipid storage, growth.
- Cancer link. Hyperinsulinemia stimulates IGF-1 pathway; obesity and cancer.
- Cardiovascular disease. Insulin resistance is a CV risk factor (metabolic syndrome).
- Drug development. GLP-1 agonists, SGLT2 inhibitors emerged from glucose-handling biology.
- Hypoglycemia management. Excess insulin causes life-threatening lows in diabetics.
Common misconceptions
- Insulin only handles glucose. Major effects on lipid storage and protein synthesis.
- Type 2 diabetes is "mild." Same complications as type 1 over time.
- Insulin causes diabetes. Reverse — insufficient insulin or resistance causes diabetes.
- Sugar consumption directly causes diabetes. Risk rises with obesity broadly; sugar contributes via calories.
- Insulin doses are universal. Highly individualized — type, weight, diet, activity, illness.
- HbA1c is fasting glucose average. Reflects ~3-month average overall glycemia (RBC lifespan ~120 days).
Frequently asked questions
How does insulin signaling work?
Insulin binds α subunits of the receptor; β subunits autophosphorylate on tyrosine residues. Active receptor phosphorylates IRS-1 and IRS-2 (insulin receptor substrates). IRS recruits PI3K, generating PIP3 at the membrane. PIP3 activates PDK1 and Akt (PKB). Akt phosphorylates AS160, releasing Rab GTPases that mobilize GLUT4 vesicles to the membrane. Akt also inhibits FOXO1 (suppresses gluconeogenesis), activates glycogen synthase (via inhibiting GSK-3β), and promotes lipogenesis (via SREBP-1c).
Why is GLUT4 special?
It's the only insulin-regulated glucose transporter — sequestered intracellularly until insulin signal arrives. ~95% of postprandial glucose uptake into muscle and fat depends on GLUT4 translocation. Other glucose transporters: GLUT1 (ubiquitous, basal uptake including brain and RBCs), GLUT2 (liver, β cells, low affinity glucose sensor), GLUT3 (neurons, high affinity), GLUT5 (fructose). Exercise also stimulates GLUT4 translocation via AMPK — independent of insulin, why exercise lowers glucose in diabetes.
What's the difference between type 1 and type 2 diabetes?
Type 1: autoimmune T cell destruction of β cells (anti-GAD, anti-IA-2 antibodies); ~5-10% of diabetes; usually onset <30 yr; requires insulin from diagnosis; risk of DKA. Type 2: insulin resistance (muscle, liver, fat) plus progressive β cell failure; ~90% of cases; strongly tied to obesity and inactivity; manageable initially with lifestyle, metformin, GLP-1 agonists, SGLT2 inhibitors; insulin added later. Both share hyperglycemia and complications (retinopathy, nephropathy, neuropathy, CV disease).
How does metformin work?
First-line oral agent for type 2 diabetes (~150 million prescriptions/yr globally). Activates AMPK in liver, decreasing hepatic gluconeogenesis (main mechanism). Modestly improves peripheral insulin sensitivity. Doesn't cause hypoglycemia or weight gain. Side effects: GI upset (start low — 500 mg with meals), B12 deficiency (long-term), rare lactic acidosis (avoid in advanced CKD eGFR <30). HbA1c reduction ~1-1.5%.
What are GLP-1 agonists?
Mimic glucagon-like peptide-1, a gut hormone (incretin) released after meals. Stimulate insulin secretion only when glucose is elevated (low hypoglycemia risk), suppress glucagon, slow gastric emptying, reduce appetite. Drugs: semaglutide (Ozempic, Wegovy), liraglutide, dulaglutide, tirzepatide (dual GLP-1/GIP). Weight loss 10-20%; reduce CV events; transformed obesity and T2DM treatment. Side effects: nausea, rare pancreatitis, gastroparesis. ~$1,000/month US.
What's diabetic ketoacidosis (DKA)?
Insulin deficiency drives lipolysis; free fatty acids overwhelm β-oxidation; acetyl-CoA accumulates and shifts to ketone bodies (β-hydroxybutyrate, acetoacetate, acetone). Anion gap metabolic acidosis. Clinical: hyperglycemia (>250 mg/dL), pH <7.3, bicarbonate <18, ketonuria, Kussmaul respiration, fruity breath, dehydration. Treatment: IV fluids (NS), insulin infusion (0.1 U/kg/hr), potassium repletion (insulin drives K+ intracellular), search for trigger (infection, missed dose, MI).
Why does insulin cause weight gain?
Insulin promotes anabolic state — drives glucose into cells (storage as glycogen and fat), inhibits lipolysis, suppresses gluconeogenesis. Also reduces glucosuria (calories no longer lost in urine). Patients starting insulin often gain 2-4 kg. Why GLP-1 agonists, SGLT2 inhibitors, metformin (weight neutral or loss) are preferred earlier in T2DM. Type 1 diabetes "diabulimia" — patients restrict insulin to lose weight, severely dangerous.